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Summary Bacteriochlorin a (BCA), a derivative of bacteriochlorphyll a, is an effective photosensitiser in vitro
and in vivo. BCA has a major absorption peak at 760 nm where tissue penetration is optimal. This property,
together with rapid tissue clearance promises minor skin photosensitivity. The tissue localising and photo-
dynamic properties of BCA were studied using isogeneic RMA mammary tumours, transplanted into sub-
cutaneous tissue in transparent 'sandwich' observation chambers on the back of WAG/Rij rats. The fluor-
escence kinetics following an i.v. administration of 20 mgkg-' BCA was assessed in blood vessels, tumour and
normal tissue. Subsequently, the development of vascular- and tissue damage after a therapeutic light dose
(760 nm, 600 Jcm-2) was observed. Fifteen minutes post injection (p.i.), the fluorescence of BCA in the
tumour reached a plateau value of 2.5 times the fluorescence in the normal tissue. From 1 h post injection the
tumour fluorescence diminished gradually; after 24 h, the tumour fluorescence signal did not exceed that of the
normal tissue. Following photodynamic therapy (PDT), 24 h p.i., complete vascular stasis was observed 2 h
post treatment in the tumour only, with subsequent recovery. The presence of viable tumour cells following
PDT was assessed by histology and re-transplantation of treated tumour tissue from the chamber into the
flank immediately or 7 days after treatment. In both cases tumour regrowth was observed. BCA-PDT
(20mg kg-', 760 nm, 100Jcm-2) h after BCA administration, an interval which gives the optimal
differential between tumour and normal tissue, was sufficient to prevent tumour regrowth. However, this only
occurred when re-transplantation was performed 7 days after PDT. During PDT, I h p.i., vascular damage in
tumour and normal tissue was considerable. Complete vascular shut-down was observed in the tumour 2 h
after therapy and in the surrounding tissues at 24 h. Circulation damage was associated with vascular spasm
and occlusion probably due to thrombi formation. Oedema was notable, especially following PDT with
600Jcm-2 at 24h p.i.
Tumour destruction by photodynamic therapy is achieved
through retention of photosensitising compounds in tissue
after injection and the subsequent activation of these com-
pounds by irradiation with light of appropriate wavelength
and dose. The photosensitiser currently evaluated in phase
III clinical trials is Photofrin®9, a derivative of hematopor-
phyrin, enriched in the photodynamically active fraction.
However, Photofrin'9 has a number of drawbacks. In partic-
ular it induces skin photosensitivity for periods up to 6 weeks
and is chemically ill defined. These drawbacks have prompted
an intensive worldwide search for new photosensitisers
(Kessel, 1990). A good candidate for 'second generation'
photosensitiser is bacteriochlorin a (BCA). BCA is a deriva-
tive of bacteriochlorophyll a and a potent photosensitiser
both in vitro and in vivo (Schuitmaker et al., 1990). Its
lipophilic nature enhances the cellular uptake of the dye
(Richter et al., 1991). Effects on mitochondria ex vivo result-
ing from therapy (Schuitmaker et al., 1991) and in vivo
tumour fluorescence have been demonstrated (Schuitmaker et
al., 1992). This photosensitiser has a major absorption peak
at 760 nm, a wavelength where tissue penetration is optimal
(Star et al., 1992). With this photosensitiser the penetration
depth of the therapeutic light and thus the treated volume
may be maximised.
The exact mechanism of tumour necrosis resulting from
PDT is still not fully elucidated. Originally it was thought
that PDT was effective only through the selective localisation
of the photosensitiser in the tumour cells. The tumour cells
were subsequently killed by singlet oxygen, produced when
the dye was irradiated with light of an appropriate wave-
length. However, there exists accumulating evidence that an
important and immediate effect of PDT is on the vasculature
of the tumour and surrounding tissues, depending on the
sensitiser used (Henderson & Dougherty, 1992). This results
in a decreasing blood flow and eventually vascular stasis
(Star et al., 1986; Franken et al., 1988; Schuitmaker et al.,
1990). The fluorescence of BCA is of practical interest in
PDT as it may be a sensitive non-contact way of detecting
otherwise occult cancers and make them accessible for reg-
ular biopsy, eventually combining potential tumour-tissue
identification and photodynamic therapy (Lam et al., 1990).
In the present paper we report on the fluorescence kinetics
of BCA and on BCA-PDT induced damage to tumour and
normal tissue circulation in vivo.
Materials and methods
Preparation ofBCA
Bacteriochlorophyll a was obtained by extraction from the
photosynthetic anaerobic bacterium Rhodospirillum rubrum
and purified according to the method of Omata et al. (1983).
The purity of the pigment was checked by thin-layer chrom-
atography (TLC). Using an eluent of 93% methanol and 7%
phosphate buffer (pH 7, 10 mM), the bacteriochlorophyll a
yielded a single blue spot (relative mobility approximately
0.5) on Machery-Nagel Nano-Sil C,8-100 TLC plates (Diiren,
Germany). Bacteriochlorophyllin a was obtained by saponi-
fying bacteriochlorophyll a as described by Oster et al.
(1964). The central magnesium ion of bacteriochlorophyllin a
was removed with 50Mm sodium acetate (Ph4.5), and the
BCA formed was then extracted with ethylacetate. Ethyl-
acetate was evaporated under reduced pressure, and BCA
was lyophilised overnight and stored at - 20°C in the dark
under nitrogen. Throughout the extraction and modification
procedures care was taken to work under reduced light and
at 4°C as much as possible.
For intravenous administration lyophilised BCA was dis-
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solved in 3 ml methanol; 0.15 ml propane-i :2-diol (BDH,
England) and 0.5 ml Cremophor EL (Sigma, St. Louis, USA)
were added and the mixture was shaken vigorously. There-
after the methanol was evaporated under reduced pressure
and finally the mixture was diluted with sterile 0.9% NaCl to
yield an i.v. injectable suspension with a suitable BCA con-
centration of 20 mgkg-'. For each experiment the suspen-
sion was freshly prepared and used within 2 h.
Animal model
Female WAG/Rij rats 12-14 weeks of age (ITRI-TNO, Rijs-
wijk, The Netherlands) were equipped with a transparent
observation chamber (Reinhold et al., 1979) in a dorsal skin
flap. At the end of a 3 week preparation period, approx-
imately 1 mm3 of an isogeneic mammary tumour was trans-
planted into the subcutaneous tissue in the chamber. This in
vivo model enables monitoring of fluorescence kinetics in
blood vessels, tumour and subcutaneous (normal) tissue of
the chamber following i.v. administration of a fluorescent dye
(van Leengoed et al., 1990). It is also possible to observe the
development and recovery of vascular damage in tumour-
and normal tissue after a therapeutic light dose. Through all
procedural steps HypnormO (fluanisol/fentanyl mixture, Jans-
sen Pharmaceuticals, Beerse, Belgium) was used as an anaes-
thetic.
Fluorescence localisation
BCA fluorescence was excited at 514.5 nm using an argon-ion
laser (Spectra Physics model 171) at the very low power
density of 0.1 mW cm-2, in order to avoid tissue damage
caused by photoactivation of the dye. BCA fluorescence was
detected through an RG 665 nm high pass filter using an
imaging system capable ofdetecting very low light levels. The
resulting digitised images were subject to image analysis yiel-
ding average grey scale values per time interval of selected
areas of interest in tumour tissue, normal tissue and a blood
vessel.
Photodynamic therapy
Light of 760 nm wavelength was obtained from a dye laser
(Spectra Physics 375B, with Styryl 8), pumped by an argon-
ion (Spectra Physics 171) laser. Light, at a power density of
100 mW/cm 2, was delivered to the chamber via an optical
fibre and a lens system with diaphragm yielding a uniform
beam of 10 mm diameter covering the entire window of the
chamber (9 mm in diameter). Two groups of six animals were
treated. In the first group fluorescence was studied and PDT
was performed 24 h p.i. of BCA, with a light dose of
600 J cm-2. In the second group PDT was performed 1 h p.i.,
with a light dose of 100 J cm-2.
Experimentalprocedure
The experiments were performed on well vascularised cham-
bers and with vital tumours of approximately 3 mm dia-
meter. The animals were immobilised by sedation and placed
on a temperature controlled positioning stage (30°C) that
enabled positioning of the chamber under the camera. Before
i.v. administration of the dye, during the observation period
of 2 h and at 24 h p.i., fluorescence recordings were made.
Each fluorescence recording was accompanied by an image of
a piece of reference material that fitted on top of the
chamber. In this way all images could be matched against the
reference, enabling correction for any fluctuations in excita-
tion light intensity or spatial variations in the sensitivity of
the imaging system.
At 24 h p.i. the chambers reviewed a therapeutic light dose.
Before, during and after the irradiation, the status of the
circulation was determined under a microscope and scored
on a scale from 0 (no observable damage) to 8 (no obser-
vable circulation). Tumour and surrounding normal tissue
were scored separately. The status of the circulation of three
animals from the group of six was determined during a 7 day
follow-up period. Then, the tumour and a margin of normal
tissue (or the necrotic remains) was removed from the
chamber and retransplanted into the flank of the same
animal. In two animals from each group the tumour and a
margin of normal tissue was retransplanted 2 h after therapy
to see whether enough damage was inflicted to prevent
tumour regrowth. Finally one chamber from each group was
prepared for histology. In the second series of six animals a
therapeutic light dose of 100 J cm-2 was delivered at a much
shorter interval of 60min p.i. Apart from that a similar
protocol was followed. All sensitised animals were kept under
reduced light conditions (<30 jiW cm-2) with a 12/12 h day/
night cycle.
Results
Digitised fluorescence images of BCA in vivo in an observa-
tion chamber are shown in Figure 1. A fluorescence angio-
gram develops following i.v. administration of BCA. The
fluorescence in the blood vessels decreases after 5 min p.i.
whereas the fluorescence in the tumour increases up to
30min p.i. Twenty-four hours after the administration tu-
mour tissue and blood vessel are undistinguishable from the
normal tissue. Also at this interval no signs of vascular or
tissue damage could be observed. Therefore the effects of
BCA alone and the excitation of fluorescence were con-
sidered negligible.
Figure 2 summarises the results of the fluorescence phar-
macokinetics study. Grey scale values measured in selected
areas of tumour, blood vessel and normal tissue are presen-
ted as a function of time following administration of BCA.
Following administration, the fluorescence in the blood
vessels decreases whereas tumour fluorescence remains at a
constant level until 60min p.i. and then starts to decrease.
Note that the fluorescence of the normal tissue hardly
changes during the observation period. When expressed as
ratios relative to normal tissue, tumour tissue fluorescence
increases to a value of 2.5 (interval of 15 min). This level is
maintained up to 60 min p.i., but at 120 min it has declined
to a ratio of 1.6. At 24 h p.i., the tumour fluorescence ratio
has dropped below 1. On average, the fluorescence of the
normal tissue then slightly exceeds that of tumour and vas-
culature. Blood vessel ratios peak immediately post injection
and at 5 min p.i. a level of 2.5 times the fluorescence of the
normal tissue is recorded. Gradually this level decreases to
become indistinguishable from the normal tissue (a ratio of
1) 2h p.i.
The circulation damage scores during and after a thera-
peutic treatment with 600 J cm-2 at 24 h p.i. are shown in
Figure 3a. Tumour vasculature appears to be damaged to a
larger extent than blood vessels in the normal tissue. Only at
2 h after therapy a maximum score of 8 (no circulation
observed) is reached for the tumour vasculature. Figure 3a
also shows that, following the protocol with a 24 h interval,
the circulation in tumour and normal tissue recovers to a
score of about 3-4 within 6-7 days. Usually the larger
vessels recover or existing smaller branches increase in dia-
meter. The damaged capillary bed is replaced by new capil-
laries. Note that during the 100 minof illumination, vascular
damage developed very slowly reaching a circulation damage
score of 3 (normal tissue) - 5 (tumour tissue) at the end of
this period. Histology performed 2 h after the treatment light
dose demonstrated the presence of viable tumour cells. With
this treatment regime, tumour regrowth after reimplantation
following therapy was never prevented, not immediately post
treatment nor after the 7 day follow up period.
In the second series of PDT treatments an interval of 1h
between i.v. administration of BCA and therapeutic illumina-
tion was chosen. This decision was based on the results of
the fluorescence kinetics study (see Figure 2). Furthermore
the light dose was reduced from 600 J cm-2to 100 Jcm-' in
view of the higher photosensitiser concentration present at
this interval. The vascular damage scores of these experi-900 H.L.L.M. VAN LEENGOED et al.
Figure 1 Digital images of the chamber model (inner diameter of 9 mm), showing the fluorescence of BCA in tumour, blood vessels and normal tissue at 5 a, 30 b, 120 min c, and at 24h p.i. d. Tumour diameter approximately 3 mm. Note the rapid clearance from the circulation and the distinct fluorescence of the tumour. Scale: white bar represents 2 mm.
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Figure 2 Fluorescence signal measured as average grey scale values of selected areas of interest of tumour, blood vessel and normal tissue as a function of time following i.v. administration of BCA. The bars represent group averages ± s.e.m. of 6, 6, 6, 5, 3 and 5 animals respectively.
ments are presented in Figure 3b. Complete vascular shut-
down was observed in the tumour 2 h after therapy, similar
to the effects seen following therapy at 24 h p.i. After 24 h
post therapy, the normal tissue had no observable circulation
either. The vascular effects were already evident after 5 min
of illumination resulting in an ischemic tumour, vascular
spasm of the arterioles as well as venules of the normal
tissue. Occlusions in the large vessles during and shortly after
therapy were possibly caused by the many thrombi that were
observed. At the end of the therapeutic irradiation there was
still some circulation present in the normal tissue (damage
score of 4). Immediate post-treatment retransplantation re-
sulted in tumour regrowth for both treatment regimes. Via-
bility of tumour cells at this interval was again confirmed by histology. Damage scores of tumour and normal tissue re-
mained maximal during the 7 day follow up and retransplan-
tation at this interval did not result in regrowth of the
tumour.
Discussion
Depending on the time between i.v. administration of the dye
and PDT and on the applied light-dose, BCA-PDT even-
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Figure 3 Circulation damage scores of tumour tissue and normal tissue for the interval between administration of BCA and
therapy of 24 h and 600 J cm-2 a, and 1 h and 100 J cm-2 b, respectively. The values are group averages of 6 animals until day 0
and 3 animals for the rest of the experiment. The damage scores range from 0 (no observable damage) to 8 (no observable
circulation). PDT (abscissa) marks the duration of illumination which is expressed in minutes. The observations at day 0 were
taken 2 h post therapy. Error margins are indicated for two representative observation periods. When a mean score of 8
(maximum) is reported, the error is zero.
tually resulted in complete vascular stasis and prevention of
tumour tissue regrowth upon reimplantation at the end of a
7 day follow-up period.
In the case of PDT using hematoporphyrin derivate (HpD)
or Photofrin@ the most common interval between administra-
tion of the photosensitiser and illumination of the tumour is
24-48 h. In a first attempt to realise a therapeutic protocol,
an interval of 24 h between i.v. administration of BCA and
the therapeutic illumination was chosen. Furthermore a BCA
dose of 20 mg kg-' was selected based on previous experience
(Schuitmaker et al., 1990). However, as Figure 3a demon-
strates, using this protocol and despite the relatively high
light dose that was applied, it was not possible to achieve
complete and irreversible vascular stasis in the observation
chamber model and tumour regrowth always occurred. This
observation coincides with the lack of selectivity and reduced
fluorescence at 24 h p.i. (Figure 2).
Therefore, in the second series of experiments the tumour
was treated 1 h after administration of the dye. The choice
for this 1 h interval was entirely based on the preceding in
vivo fluorescence kinetics study (see Table I). This study
showed that in the window chamber model, tumour selec-
Table I Ratios ± s.e.m. of tumour tissue and vessel fluorescence
relative to the fluorescence of the normal tissue for different time
intervals following administration of BCA
Time after BCA Ratios ± s.e.m.
administration Tumour Vessel
5min 1.9±0.3 2.5±0.5
15min 2.5±0.5 2.4±0.5
30 min 2.5 0.4 2.2 0.5
60min 2.4±0.4 1.8±0.5
120min 1.6±0.2 1.0±0.3
24h 0.5±0.2 0.8±0.1
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tivity up to 2.5 times the fluorescence signal of the normal
tissue can be achieved, during 15 to 60 min p.i. At 60 min p.i.
the fluorescence signal ratio of the vessels has decreased by
approximately 40% of the highest value whereas this ratio in
the tumour had dropped by less than 5% ofits highest value.
At 24 h p.i. tumour and blood vessel ratios become indistin-
guishable from the normal tissue, similar to what is observed
with HpD in the same model (van Leengoed et al., 1990).
A six fold reduction of the light dose to 100 J cm-2
(100 mWcm-2) was chosen as a higher overall concentration
of the photosensitiser was expected. This light dose resulted
in complete and irreparable vascular stasis in the observation
chamber. Furthermore, tumour regrowth was prevented in
those cases where the tumour was left in situ during the 7-day
follow up period and was subsequently retransplanted in the
flank of the same animal.
The fact that 24 h appears not to be the optimum interval
has also been noted for other photosensitisers, e.g. chlorins
(Gomer, 1991) and bacteriochlorophyll a (Henderson et al.,
1991). As is shown above, the fluorescence kinetics in vivo
can be used to determine a 'therapeutic window' i.e. a
suitable time interval between dye administration and PDT.
This is different from HpD-PDT, where in this observation
chamber model, 2 h p.i., tumour fluorescence could be dis-
criminated from normal tissue in only 40-50% of the cases
(van Leengoed et al., 1990). In this model complete necrosis
required a light dose of 160 J cm-2 at 630 nm applied 24 h
p.i. of 15 mg kg-' HpD (Star et al., 1986). Although vascular
effects are not the primary target ofthe therapy, the resulting
sterilisation of the tumour-bed will prevent nutritional resup-
ply to still viable tumour cells through diffusion or angio-
genesis (Fingar & Henderson, 1987) thereby enhancing the
effect of the therapy.
The circulation damage scores (Figure 3a) of the PDT
treatment at 24 h p.i. show a differential effect on the vas-
culature of the tumour tissue and the normal tissue. This
might be partly explained by the fact that in this model,
tumour tissue only contains capillaries whereas the normal
tissue contains capillaries and larger vessels. A maximum
damage score is reached only 2 h after therapy and only in
the tumour; from then on the circulation of tumour and
normal tissue recovers. As a result, PDT treatment 24 h p.i.
of BCA rendered no 'cures'. At this interval no fluorescence
could be detected in the tumour nor in vessels which in this
case could indicate that the BCA concentration in the vessels,
tumour and normal tissue was too low to be effective. When
a 24 h interval between administration and therapy was
studied, the blood supply to the tumour was maintained
during an illumination time of at least 60 min (360 JcMu2).
This delayed vascular shut down might increase the direct
tumour cell kill as this is dependent on the availability of
oxygen. Nevertheless, enough tumour cells apparently es-
caped therapy, causing tumour regrowth in all cases. With
only 1 h between administration and therapy, where BCA
fluorescence was still detectable in the vasculature, 30 J cm-2
( = 5 min of illumination) resulted in higher circulation dam-
age scores than 600 J cM-2 of light at the 24 h interval. Five
minutes after the start of illumination, vascular spasms, cir-
culating and occluding thrombi were observed. These direct
vascular effects have also been reported during porphyrin
based PDT (Star et al., 1986; Reed et al., 1988).
Following 100 J cM-2 of light applied 1 h p.i., the tumour-
and normal tissue damage was sufficient to prevent tumour
regrowth following retransplantation at day 7. Two hours
post therapy re-transplantation yielded regrowth of the tu-
mour, demonstrating the presence of viable tumour cells at
this time. This observation agrees with the findings of
Henderson (1992) that cells removed immediately after PDT
can be viable in vitro, and stresses the role of tumour-bed
damage in determining the final outcome of photodynamic
therapy. Histology performed 2 h post therapy revealed that
individual tumour cells survived following PDT at 1 h as well
as at 24 h p.i. Probably the interval at which histology was
performed was not optimal with respect to predicting the
effectiveness of the therapy since one of the treatment
schemes was effective in preventing tumour regrowth.
Summarising, BCA is useful, not only to induce tumour
necrosis in PDT but for tumour detection by fluorescence as
well. It induces selective fluorescence from 5 to 120 min p.i.
in mammary tumours in the present model. In this respect
and in this model, BCA is a much better tumour localiser
than HpD. In vivo fluorescence of BCA can be used to
determine a suitable time interval between i.v. administration
of the dye and the subsequent therapeutic illumination of
tumour tissue. The therapeutic ratio of the dye can be in-
creased by making use of the photobleaching properties of
the dye. In vitro, a 50% decrease of the absorption of 760 nm
is observed after 86 J cM-2 (unpublished data J.J. S.). At the
end of the therapeutic treatment viable tumour cells must be
present as immediate retransplantation always results in
tumour regrowth. Vascular damage appears to be a prere-
quisite to obtain tumour control with BCA. Determining the
optimum sensitiser dose and interval between drug adminis-
tration and therapy should be the subject of further study.
This work was supported by the Dutch Cancer Society ('Kroningin
Wilhelmina Fonds'), project DDHK-89-3, and the 'Stichting Blin-
denhulp'. Funds for equipment were granted by the 'Maurits and
Anna de Kock Stichting', the 'Nijbakker, Morra Stichting' and the
'Josephine Nefkens Stichting'. The authors wish to thank Stan Sliwa
for preparing the photographs.
References
FINGAR, V.H. & HENDERSON, B.W. (1987). Drug and light dose
dependence of photodynamic therapy: a study of tumor and
normal tissue response. Photochem. Photobiol., 46, 837-841.
FRANKEN, N.A.P., VRENSEN, G.F.J.M., VAN DELFT, J.L., DE WOLFF-
ROUENDAAKL, D., DUBBELMAN, T.M.A.R., OOSTERHUIS, J.A.,
STAR, W.M. & MARIJNISSEN, J.P.A. (1988). Early morphological
changes induced by photodynamic therapy in amelanotic Greene
melanoma implanted in the anterior eye chamber of rabbits.
Lasers Med. Sci., 3, 27-34.
GOMER, C.J. (1991). Preclinical examination of first and second
generation photosensitizers used in photodynamic therapy. Pho-
tochem. Photobiol., 54, 1093-1107.
HENDERSON, B.W. & DOUGHERTY, T.J. (1992). How does photo-
dynamic therapy work? Photochem. Photobiol., 55, 145-157.
HENDERSON, B.W., SUMLIN, A.B., OWCZARCZAK, B.L. & DOUG-
HERTY, T.J. (1991). Bacteriochlorphyll-a as photosensitizer for
photodynamic treatment of transplantable murine tumors. J.
Photochem. Photobiol. B: Biology, 10, 303-313.
KESSEL, D. (1990). HPD: Structure and determinants of localisation.
In Photodynamic Therapy of Neoplastic Disease, Volume II,
Kessel, D. (ed). pp. 1-15. CRC Press: Boca Raton, Florida.
LAM, S., PALCIC, B., MCLEAN, D., HUNG, J., KORBELIK, M. &
PROFIO, A.E. (1990). Detection of early lung cancer using low
dose Photofrin II. Chest, 97, 333-337.
OMATA, T. & MURATA, N. (1983). Preparation of chlorophyll a,
chlorophyll b, and bacteriochlorophyll a by column chromatog-
raphy with DEAE Sepharose CI-6B and Sepharose CI-6B. Plant
Cell Physiol., 25, 1093-1100.
OSTER, G., BROYDE, B. & BELLIN, J.S. (1964). Spectral properties of
chlorophyllin a. J. Am. Chem. Soc., 5, 1309-1313.
REED, M.W.R., MILLER, F.N., WIEMAN, T.J., TSENG, M.T. & PIE-
TSCH, C.G. (1988). The effect of photodynamic therapy on the
microcirculation. J. Surg. Res., 45, 452-459.
REINHOLD, H.S., BLACHIEWICZ, B. & VAN DEN BERG-BLOK,. A.E.
(1979). Reoxygenation of tumors in 'sandwich' chambers. Eur. J.
Cancer, 15, 481-489.
RICHTER, A.M., WATERFIELD, E., JANE, A.K., ALLISON, B., STERN-
BERG, E.D., DOLPHIN, D. & LEVY, J.G. (1991). Photosensitizing
potency of structural analogues of benzoporphyrin derivative
(BPD) in a mouse tumour model. Br. J. Cancer, 63, 87-93.IN VIVO FLUORESCENCE AND PDT OF BACTERIOCHLORIN A 903
SCHUITMAKER, J.J., FRENSEN, G.F.J.M., VAN DELFT, J.L., DE
WOLFF-ROUENDAAL, D., DUBBELMAN, T.M.A.R. & DE WOLF,
A. (1991). Morphologic effects of bacteriochlorin a and light in
vivo on intraocular melanoma. Invest. Ophthalmol. Vis. Sci,. 32,
2683-2688.
SCHUITMAKER, J.J., VAN BEST, J.A., VAN DELFT, J.L., DUBBELMAN,
T.M.A.R., OOSTERHUIS, J.A. & DE WOLFF-ROUENDAAL, D.
(1990). Bacteriochlorin a, a new photosensitizer in photodynamic
therapy. In vivo results. Invest. Ophthalmol. Vis. Sci., 31, 1444-
1450.
SCHUITMAKER, J.J., VAN LEENGOED, E., VAN DER VEEN, N., DUB-
BELMAN, T.M.A.R. & STAR, W.M. (1992). Laser-induced in vivo
fluorescence ofbacteriochlorin a: preliminary results. Lasers Med.
Sci., (in press).
STAR, W.M., MARIJNISSEN, J.P.A., VAN DEN BERG-BLOK, A.E., VER-
STEEG, A.A.C., FRANKEN, N.A.P. & REINHOLD, H.S. (1986).
Destruction of rat mammary tumor and normal tissue microcir-
culation by hematoporphyrin derivative photoradiation observed
in vivo in sandwich observation chambers. Cancer Res., 46,
2532-2540.
STAR, W.M., WILSON, B.C. & PATrERSON, M.S. (1992). Light de-
livery and optical dosimetry in photodynamic therapy of solid
tumors. In: Photodynamic Therapy, Henderson, B.W. & Doug-
herty, T.J. (ed). pp. 335-368. Marcel Dekker: New York.
VAN LEENGOED, E., VERSTEEG, A.A.C., VAN DER VEEN, N., VAN DEN
BERG-BLOK, A.E., MARIJNISSEN, J.P.A. & STAR, W. (1990).
Tissue-localizing properties of some photosensitizers studied by in
vivo fluorescence imaging. J. Photochem. Photobiol. B: Biology, 6,
111-119.